Skeletal muscle index-to-body mass index ratio as a predictor of postsurgical bleeding after mastectomy in patients with breast cancer

doi:10.21203/rs.3.rs-2859431/v1

Download PDF

Research Article

Skeletal muscle index-to-body mass index ratio as a predictor of postsurgical bleeding after mastectomy in patients with breast cancer

https://doi.org/10.21203/rs.3.rs-2859431/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 12 Jul, 2023

Read the published version in Breast Cancer →

You are reading this latest preprint version

Background

Postsurgical bleeding is a major complication of mastectomy in patients with breast cancer. However, the risk factors for postsurgical bleeding have not been well studied. Although obesity or reduced skeletal muscle mass is an indicator of cancer surgery complications, its impact on postsurgical bleeding after mastectomy remains unknown.

Methods

In total, 563 patients with breast cancer who underwent mastectomy were included in this study. We evaluated the preoperative body mass index (BMI), skeletal muscle index (SMI), and SMI-to-BMI ratio and analyzed the association between these values and the incidence of postsurgical bleeding.

Results

Postsurgical bleeding occurred in 33 (5.6%) patients. Mean BMI was significantly higher in the bleeding group (26.3 ± 4.7) than in the no bleeding group (23.0 ± 4.1) (p < 0.001), whereas mean SMI was lower in the former group (45.0 ± 8.5) than in the latter group (48.0 ± 8.5) (p = 0.08). The bleeding group had significantly lower SMI-to-BMI ratio (1.71 ± 0.16) than the no bleeding group (2.10 ± 0.23) (p < 0.001). Among these three parameters, SMI-to-BMI ratio had the highest area under the curve value in their receiver operating characteristic curves (0.73 for BMI, 0.59 for SMI, 0.92 for SMI-to-BMI ratio). Furthermore, on multivariate analysis, SMI-to-BMI ratio was an independent risk factor for postsurgical bleeding (hazard ratio, 38.4; 95% confidence interval, 13.9–136.2; p < 0.001).

Conclusions

SMI-to-BMI ratio is a superior predictive factor of postsurgical bleeding after mastectomy to either BMI or SMI alone.

Skeletal muscle index

Body mass index

Postsurgical bleeding

Mastectomy

Breast cancer

Breast cancer is the most frequent solid malignancy in women and one of the leading causes of cancer-related death worldwide [1]. Despite recent progress in pharmacotherapy (chemotherapy, molecular targeting therapy, and endocrine therapy) and radiation therapy, surgery remains the cornerstone of early breast cancer treatment. Although breast-conserving surgery followed by whole-breast irradiation is a widely accepted treatment for women with relatively small breast cancers [2], mastectomy has main choice of surgical procedure, particularly for patients with widespread breast cancers or those who cannot receive radiation therapy [3].

Major complications of mastectomy include postsurgical bleeding, surgical site infection, seroma formation, and skin flap necrosis [4–6]. Among them, postsurgical bleeding is one of the clinically significant complications because it can require blood transfusion or reoperation to control bleeding, although it may rarely be fatal. Even if this is not the case, this complication can delay drain removal and consequently prolong hospital stay. Hence, it is imperative for breast surgeons to avoid postsurgical bleeding by elucidating the predictive factors for this complication.

Several previous reports have indicated obesity as a risk factor for postoperative complications following breast surgeries [5–10]. Garland et al. demonstrated that high body mass index (BMI) was associated with bleeding risk after mastectomy [8]. On the other hand, increasing evidence suggests that sarcopenia, which is characterized by skeletal muscle loss and decreased physical activity [11], is correlated with the incidence of complications associated with surgery for various solid malignancies, including lung, colorectal, and hepatobiliary cancers [12–14]. Accordingly, the skeletal muscle index (SMI), which is standardized by calculating the ratio of skeletal muscle area (SMA) at the third lumbar vertebral level divided by the square of the height, is an indicator of complications after surgery for lung and gastrointestinal cancers [15, 16]. However, no study has investigated the association between SMI and frequency of complications after breast surgery. Hence, whether SMI correlates with the incidence of postsurgical bleeding after mastectomy remains unknown.

This study aimed to explore the risk factors for postsurgical bleeding after mastectomy in patients with breast cancer. To this end, we evaluated the preoperative BMI, SMI, and SMI-to-BMI ratio in patients who underwent mastectomy and investigated the association between these values and the incidence of postsurgical bleeding.

Patients and study design

We retrospectively assessed patients with breast cancer who underwent surgery at Shinshu University Hospital between December 2015 and January 2022. The inclusion criteria were as follows: (1) patients who had pathologically confirmed breast cancer by core needle biopsy or vacuum-assisted biopsy, (2) those who underwent computed tomography (CT) before surgery, and (3) those who underwent mastectomy. Type of surgical procedure for the axillary lymph nodes (none, sentinel lymph node biopsy [SLNB], or axillary dissection [Ax]) was not mattered to be included in this study. Patients who underwent one-stage reconstruction and male patients were excluded from this study. In total, 563 patients were included in this study. As 21 patients had synchronous bilateral breast cancer and underwent bilateral mastectomy, 584 breasts were analyzed. Patients with node-positive breast cancer received neoadjuvant chemotherapy (NAC) consisting of fluorouracil-epirubicin-cyclophosphamide (FEC) (triweekly administered FEC [500 mg/m² fluorouracil, 100 mg/m² epirubicin, and 500 mg/m² cyclophosphamide]) followed by taxane regimens (triweekly administered docetaxel 75 mg/m² or weekly administered paclitaxel 80 mg/m²). Four cycles of the taxane regimen were administered after four cycles of FEC. A subset of patients with human epidermal growth factor receptor type 2 (HER2)-positive or triple-negative (TN) breast cancer were also treated with NAC even if lymph node involvement was not preoperatively confirmed. In HER2-positive patients, 6 mg/kg (triweekly) or 2 mg/kg (weekly) trastuzumab with or without 420 mg (triweekly) pertuzumab was simultaneously administered with a taxane regimen. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the local ethics committee on the clinical investigation of Shinshu University (no. 5323). Our institution uses a form on its website to enable patients to opt out of the use of their clinical data for study purposes, and the requirement for written informed consent was waived. All patient data were anonymized.

Data collection

Clinical information, including age, affected side of the breast, height, body weight, presence of NAC, surgical procedure, type of surgeon, histological type, pathological tumor size, lymph node metastasis, estrogen receptor (ER) status, progesterone receptor (PgR) status, HER2 status, length of drainage, and hospital stay, was collected from the patients’ medical records. The surgeons were stratified into two groups: resident and faculty. A faculty was defined as a board-certified surgeon at the Japan Breast Cancer Society. Breast cancer subtypes were defined as follows: luminal (ER- or PgR-positive and HER2-negative), luminal HER2 (ER- or PR-positive and HER2-positive), HER2-enriched (ER- and PR-negative, HER2-positive), and TN (ER-, PR-, and HER2-negative). For patients who underwent mastectomy with SLNB or simple mastectomy, a 15Fr J-VAC® (Johnson & Johnson, NJ) drain was placed at the subcutaneous space of the breast. For patients undergoing mastectomy with Ax, another 15Fr J-VAC® drain was placed at the axilla, in addition to a subcutaneous drain. Drainage duration was defined as duration (days) from the surgery to the day when all the J-VAC® drains were removed.

Definition of postsurgical bleeding

We routinely compressed the wound with a bust band to prevent postsurgical bleeding. If we suspected postsurgical bleeding with swelling of the wound or the continuous bloody discharge from the J-VAC® drain, we attempted hemostasis by placing a layer of gauze over the wound and manually compressing the bleeding point. In this study, postsurgical bleeding was defined as a hemorrhage requiring postoperative manual compression or bloody drainage of > 100 ml until the morning of the day after surgery. In patients undergoing mastectomy with Ax, a bloody discharge of > 100 ml from either of the two J-VAC® drains was considered postsurgical bleeding. The J-VAC® drain was removed when the drainage volume was < 25 ml per day.

Measurement of skeletal muscle index (SMI)-to-body mass index (BMI) ratio

Preoperative CT was performed within 1 month prior to the surgery. For patients receiving NAC, CT was performed > 3 weeks after the completion of NAC. SMA was measured using preoperative CT images, irrespective of the administration of NAC. SMA was measured as the cross-sectional area of the surrounding muscles (i.e., psoas, paraspinals, transversus abdominis, rectus abdominis, and internal and external obliques) by semiautomatic tracing using images at the third lumbar vertebral level visualized within a range of − 29 to 150 Hounsfield units using the EV Insite R (PSP Corporation, Tokyo, Japan) system and expressed in cm². SMI was calculated as the ratio of SMA divided by height squared (m²), whereas BMI was calculated as body weight (kg) divided by height squared (m²). Body weight within 1 month prior to the surgery was used to calculate BMI. The preoperative SMI-to-BMI ratio was calculated by dividing SMI by BMI. The receiver operating characteristic (ROC) curve was analyzed to determine the best BMI, SMI, and SMI-to-BMI ratio cutoff values for postsurgical bleeding.

Statistical analyses

Categorical variables were analyzed using the chi-squared test, whereas continuous variables were analyzed using two-sided t-tests. Univariate and multivariate analyses using a logistic regression model were performed to determine the significant factors for postsurgical bleeding. Multivariate analysis was performed for parameters with p < 0.3 in the univariate analysis. All statistical analyses were performed using GraphPad Prism 9.3.1 (GraphPad Software, CA, USA), and p < 0.05 was considered statistically significant.

Patient characteristics

The clinicopathological characteristics of the studied cases are shown in Table 1. The mean age of the patients (± standard deviation) was 59.2 ± 14.2 years. In total, 270 (46.2%) and 314 (53.8%) patients had right and left breast cancers, respectively. The mean preoperative BMI and SMI were 23.0 ± 3.7 and 47.3 ± 7.4, respectively. In total, 136 (23.3%) patients received NAC. Regarding surgical procedures, 250 (42.8%) underwent mastectomy with Ax, whereas 334 (57.2%) underwent mastectomy with SLNB or simple mastectomy. Regarding the type of surgeon, 210 mastectomies (36.0%) were performed by residents, whereas the other 374 cases (64.0%) were performed by faculties. Regarding pathological classification, 467 (79.5%), 49 (8.4%), and 71 (12.1%) cases were ductal carcinoma, lobular carcinoma, and other special types of carcinoma, respectively. Ninety-four cases (16.1%) were ductal carcinoma in situ or no remnant invasive cancer after NAC (pathological complete response), 272 were tumors ≤ 2.0 cm (46.6%), and 218 were tumors > 2.0 cm (37.3%). Lymph nodes were pathologically involved in 191 cases (32.7%). Regarding the pathological stage of the resected specimens, 94 (16.1%), 215 (36.8%), 198 (33.9%), 68 (11.6%), and 10 (1.6%) cases were 0, I, II, III, and IV pathological stages, respectively. Regarding the intrinsic subtype, 361 (61.8%), 94 (16.2%), 47 (8.0%), and 79 (13.5%) cases were luminal, luminal HER2, HER2-enriched, and TN breast cancer, respectively.

Table 1

Clinicopathological characteristics of patients and comparison between the bleeding and no bleeding group
Variables		Total	No bleeding	Bleeding
		n = 584 (%)	n = 551 (%)	n = 33 (%)	p value
Age (mean ± SD)		59.2 ± 14.2	59.2 ± 14.4	59.2 ± 13.1	0.99
Affected breast	Right	270 (46.2)	254 (46.1)	16 (48.5)	0.79
	Left	314 (53.8)	297 (53.9)	17 (51.5)
NAC	Present	136 (23.3)	136 (24.7)	0 (0)	< 0.001
	Absent	448 (76.7)	415 (75.3)	33 (100)
Axillary procedure	None or SLNB	334 (57.2)	306 (55.5)	28 (84.8)	< 0.001
	Ax	250 (42.8)	245 (44.5)	5 (15.2)
Surgeon	Resident	210 (36.0)	201 (36.5)	9 (27.3)	0.28
	Faculty	374 (64.0)	350 (63.5)	24 (72.7)
Histological type	Ductal	464 (79.5)	439 (79.7)	25 (75.8)	0.51
	Lobular	49 (8.4)	47 (8.5)	2 (6.1)
	Other	71 (12.1)	65 (11.8)	6 (24.2)
Tumor size	DCIS or pCR	94 (16.1)	86 (15.6)	8 (7.7)	0.75
	≤ 2.0cm	272 (46.6)	256 (46.5)	16 (53.8)
	> 2.0cm	218 (37.3)	209 (37.9)	9 (38.5)
pN	Positive	191 (32.7)	187 (33.9)	4 (12.1)	< 0.01
	Negative	393 (67.3)	364 (66.1)	29 (87.9)
pStage	0	94 (16.1)	85 (15.4)	9 (25.8)	0.07
	I	215 (36.8)	199 (36.1)	16 (48.4)
	II	198 (33.9)	189 (34.3)	9 (25.8)
	III	68 (11.6)	68 (12.3)	0 (0)
	IV	10 (1.6)	10 (1.9)	0 (0)
Subtype	Luminal	361 (61.8)	341 (61.9)	20 (63.6)	0.29
	Luminal HER2	94 (16.2)	88 (16.0)	6 (18.2)
	HER2 enriched	47 (8.0)	42 (7.6)	5 (15.1)
	Triple negative	79 (13.5)	77 (14.0)	2 (3.1)
	Unknown	3 (0.5)	3 (0.5)	0 (0)
SMI (mean ± SD)		47.3 ± 7.4	48.0 ± 7.5	45.0 ± 8.5	0.08
BMI (mean ± SD)		23.0 ± 3.7	23.0 ± 4.1	26.3 ± 4.7	< 0.001
NAC: Neoadjuvant chemotherapy, SLNB: Sentinel lymph node biopsy, Ax: Axillary dissection, DCIS: Ductal carcinoma in situ, pCR: Pathological complete response, HER2: Human epidermal growth factor receptor type 2, BMI: Body mass index, SMI: Skeletal muscle index,

Comparison of clinicopathological characteristics according to the presence of postsurgical bleeding

Overall, postsurgical bleeding was observed in 33 (5.6%) cases. We divided the patients into two groups according to the presence of postsurgical bleeding (no bleeding group, n = 551; bleeding group, n = 33) and compared the clinicopathological characteristics of these two groups (Table 1). There were no differences in clinicopathological features, including age, laterality of the primary tumor, type of surgeon, histological type, tumor size, lymph node metastases, pathological stage, and subtype, between the no bleeding and bleeding groups. The frequency of patients who received NAC, underwent mastectomy plus Ax, and had pathologically node-positive breast cancer was significantly lower in the bleeding group than in the no bleeding group (p < 0.001 for NAC, p < 0.001 for surgical procedure, and p < 0.01 for lymph node metastases). As for SMI, the bleeding group (45.0 ± 8.5) showed lower SMI than the no bleeding group (48.0 ± 7.5), although the difference did not reach statistical significance (p = 0.08). On the other hand, BMI was significantly higher in the bleeding group (6.3 ± 4.7) than in the no bleeding group (23.0 ± 4.1) (p < 0.001) (Table 1).

Comparison of postoperative course according to the presence of postsurgical bleeding

We compared the drainage volume until the morning of the day after surgery, drainage duration, and postoperative hospital stay between the no bleeding and bleeding groups (Table 2). Patients undergoing mastectomy with SLNB or simple mastectomy held one drain in the subcutaneous space of the breast, whereas those undergoing mastectomy plus Ax held an additional drain at the axilla, as described in the Methods section. Hence, in this analysis, we stratified the patients into two groups according to the presence of Ax (none or SLNB: n = 334, Ax group: n = 250). In the Ax group, the amount of drainage from both the subcutaneous and axillary drains was significantly greater in the bleeding group than in the no bleeding group (subcutaneous drain: 23.2 ± 16.4 in the no bleeding group vs. 159.0 ± 111.8 in the bleeding group, p < 0.001; axillary drain: 38.8 ± 22.6 in the no bleeding group vs. 220.8 ± 238.6 in the bleeding group, p < 0.001). Similarly, in the none or SLNB group, the bleeding group had significantly higher drainage volume from the subcutaneous drain compared with the no bleeding group (33.8 ± 21.9 in the no bleeding group vs. 178.7 ± 128.3 in the bleeding group, p < 0.001). Among the 33 cases with postsurgical bleeding, one required reoperation to stop postsurgical bleeding. In this case, within the first 3 h after mastectomy with SLNB, the output of bloody discharge from the subcutaneous drain reached 156 ml, despite manual compression efforts. Consequently, we deemed it necessary to perform a reoperation to control the persistent bleeding.

Table 2

Comparison of postoperative course between the no bleeding group and the bleeding group
Axillary procedure	Variables		No bleeding	Bleeding	p value
Ax (n = 250)			(n = 245)	(n = 5)
	Drainage volume until the morning of one day after surgery (ml) (mean ± SD)	Subcutaneous drain Axillary drain	23.2 ± 16.4 38.8 ± 22.6	159.0 ± 111.8 220.8 ± 238.6	< 0.001 < 0.001
	Drainage duration (days) (mean ± SD)		5.4 ± 1.7	6.5 ± 0.5	0.06
	Postoperative hospital stay (days) (mean ± SD)		8.0 ± 2.8	10.0 ± 2.1	0.08
None or SLNB (n = 334)			(n = 306)	(n = 28)
	Drainage volume until the morning of one day after surgery (ml) (mean ± SD)	Subcutaneous drain	33.8 ± 21.9	178.7 ± 128.3	< 0.001
	Drainage duration (days) (mean ± SD)		3.5 ± 1.2	5.8 ± 2.1	< 0.001
	Postoperative hospital stay (days) (mean ± SD)		7.0 ± 2.2	8.0 ± 2.2	0.01
SLNB: Sentinel lymph node biopsy, Ax: Axillary dissection,

Table 3 Univariate and multivariate Logistic regression analysis for post-surgical bleeding
		Univariate			Multivariate
Variables		p value	HR	95%CI	p value	HR	95%CI
	Age (≥ 55 vs. < 55)	0.60	1.27	0.60–2.55
	Affected breast (right vs. left)	0.79	1.10	0.54–2.23
	Surgeon (faculty vs. resident)	0.27	1.53	0.72–3.54	0.35	0.45	0.06–2.06
	Pathological tumor size (≥ 2cm vs. < 2cm)	0.21	0.61	0.27–1.30	0.66	1.34	0.34–4.97
	Axillary procedure (Ax vs. none or SLNB)	< 0.001	0.22	0.07–0.54	0.08	0.23	0.03–1.01
	SMI-to-BMI ratio (< 1.88 vs. ≥ 1.88)	< 0.001	37.6	14.3–129.2	< 0.001	38.4	9.52–259.3
Ax: Axillary dissection, SLNB: Sentinel lymph node biopsy, SMI: Skeletal muscle index, BMI: Body mass index

As for drainage duration and postoperative hospital stay, in the Ax group, there was a tendency that drainage duration (5.4 ± 1.7 in the no bleeding group vs. 6.5 ± 0.5 in the bleeding group, p = 0.06) and postoperative hospital stay (8.0 ± 2.8 in the no bleeding group vs. 10.0 ± 2.1 in the bleeding group, p = 0.08) were longer in the bleeding group than in the no bleeding group. In the none or SLNB group, both drainage duration (3.5 ± 1.2 in the no bleeding group vs. 5.8 ± 1.2 in the bleeding group, p < 0.001) and postoperative hospital stay (7.0 ± 2.2 in the no bleeding group vs. 8.0 ± 2.2 in the bleeding group, p = 0.01) were significantly longer in the bleeding group than in the no bleeding group. These results indicate that postsurgical bleeding might delay drain removal and prolong the hospital stay.

Correlation between preoperative SMI and BMI

BMI is positively correlated with SMI in patients with cancer [17]. In the patient cohort in this study, BMI and SMI showed a significant positive correlation (p < 0.001, R = 0.54) in our breast cancer cohort (Fig. 1a). Subsequently, we examined whether there were any differences in the correlation between SMI and BMI in the no bleeding and bleeding groups, and the scatterplot in which each patient in the bleeding and no bleeding groups was individually indicated suggested that patients in the bleeding group were susceptible to having a low SMI for BMI (Fig. 1b).

Based on this observation, we hypothesized that low SMI for BMI may be a predictive factor for postsurgical bleeding and that low SMI was significantly associated with the incidence of postsurgical bleeding in patients with similar BMI. To test this hypothesis, we stratified the patients into two groups according to a BMI of 25 kg/m² and compared the SMI in each group. Subsequently, patients in the bleeding group had significantly lower SMI than those in the no bleeding group in both the BMI ≥ 25 kg/m² (55.3 ± 7.5 in the no bleeding group vs. 50.6 ± 7.5 in the bleeding group, p = 0.02) and the BMI < 25 kg/m² group (44.9 ± 5.8 in the no bleeding group vs. 39.0 ± 5.1 in the bleeding group, p < 0.001) (Fig. 2).

Impact of SMI-to-BMI ratio as a risk factor for postsurgical bleeding

Given that low SMI was associated with the incidence of postsurgical bleeding in patients with similar BMI, we next hypothesized that standardization of SMI by BMI provided a more accurate risk factor for postsurgical bleeding than the single use of BMI or SMI. To address this, we calculated the SMI-to-BMI ratio and compared its values between the no bleeding and bleeding groups. The SMI-to-BMI ratio in the bleeding group was significantly lower (1.71 ± 0.16) than that in the no bleeding group (2.10 ± 0.23) (p < 0.001) (Fig. 3).

To determine the factors that have the highest accuracy for predicting postsurgical bleeding among BMI, SMI, and SMI-to-BMI ratio, we compared the area under the curve (AUC) of these three factors in the ROC curves. The SMI-to-BMI ratio had a higher AUC (0.92, sensitivity/specificity = 0.84, cutoff value = 1.88) than BMI (AUC = 0.73, sensitivity/specificity = 0.66, cutoff value = 23.6) and SMI (AUC = 0.59, sensitivity/specificity = 0.60, cutoff value = 45.2) (Fig. 4).

Subsequently, to explore the factors independently associated with the risk of postsurgical bleeding, univariate and multivariate analyses were performed. Univariate analysis revealed that axillary procedure (none or SLNB) (hazard ratio [HR], 0.22; 95% confidence interval [CI], 0.07–0.54; p < 0.001) and low SMI-to-BMI ratio (HR, 37.6; 95% CI, 14.3–129.2; p < 0.001) were significantly associated with postsurgical bleeding (Table 3). On multivariate analysis using the logistic regression analysis, only low SMI-to-BMI ratio was an independent factor for this complication (HR, 38.4; 95% CI, 9.15–259.3; p < 0.001).

Impact of sarcopenic obesity as a risk factor for postsurgical bleeding

Patients with low SMI-to-BMI ratio is associated with a condition having high BMI and low SMI. This condition is in accordance with the concept of sarcopenic obesity, which has recently gained considerable attention as a superior marker to sarcopenia for predicting the prognosis and postoperative complications in patients with cancer [17–20]. To evaluate the impact of sarcopenic obesity, we stratified the patients into four groups (high-SMI/low-BMI, high-SMI/high-BMI, low-SMI/low-BMI, and low-SMI/high-BMI). The optimal cutoff values for BMI and SMI determined by the ROC analysis were 23.6 (AUC = 0.73, sensitivity/specificity = 0.66) and 45.2 (AUC = 0.59, sensitivity/specificity = 0.60), respectively. The incidence rate of postsurgical bleeding was highest in the low-SMI/high-BMI group (27.5%) and gradually decreased toward the low-SMI/low-BMI (20.4%), high-SMI/high-BMI (1.4%), and high-SMI/low-BMI groups (0.4%), with statistical significance (p < 0.001) (Table 4).

This study demonstrated that the SMI-to-BMI ratio was a superior indicator of postsurgical bleeding compared with BMI or SMI alone. To the best of our knowledge, this is the first study to show that a low SMI-to-BMI ratio is a risk factor for postsurgical bleeding in patients with breast cancer who undergo mastectomy.

Postsurgical bleeding is the second most frequent complication following surgical site infection [21]. Previous reports have shown that obesity was associated with a higher incidence of postsurgical bleeding [6–8]. This is consistent with the results of our study, which showed that patients with postsurgical bleeding had a significantly higher BMI than those without this complication. The main cause of postsurgical bleeding after mastectomy may be insufficient sealing or ligation of the vessels in front of the pectoralis major and serratus anterior muscles or in the subcutaneous fat. Abundant subcutaneous fat may make it difficult to detect small subcutaneous vessels and, consequently, may result in inadequate ligation of these vessels. Furthermore, patients with a high BMI are likely to have a high breast volume, which is associated with an increase in the subcutaneous peeling area. Hence, obese patients with abundant subcutaneous fat have a higher risk of postsurgical bleeding than patients without obesity.

Sarcopenia is correlated with physical frailty in patients with cancer. Regarding postoperative complications, sarcopenia is a risk factor for higher intraoperative blood loss or blood transfusion in surgery for gastrointestinal cancers [22, 23], indicating that sarcopenia may be associated with vulnerability of blood vessels. Hence, it can be hypothesized that low skeletal muscle mass can also be a predictive factor of bleeding after breast surgery. The results of this study showed that SMI was not significantly associated with the frequency of postsurgical bleeding. However, when patients were stratified according to the BMI of 25 kg/m², there were significant differences in SMI between the bleeding and the no bleeding groups both in the BMI ≥ 25 and < 25 kg/m² groups. This indicates that SMI has an impact on the incidence of postsurgical bleeding if patients with comparable physiques are compared; namely, a low SMI for BMI can be a predictor of postsurgical bleeding after mastectomy.

The skeletal muscle mass can vary among individuals with the same BMI. To date, no study has investigated the effects of identical SMI values in patients with different BMIs on the incidence of postoperative complications. In this regard, standardization of skeletal muscle mass by body weight may be worth investigating as a more accurate parameter to estimate the body composition and a risk factor for postoperative complications. We hypothesized that the SMI-to-BMI ratio may have the potential to predict the incidence of postsurgical bleeding more accurately than either BMI or SMI alone. The results of this study showed that the AUC of the SMI-to-BMI ratio in the ROC analysis was higher than that of BMI or SMI, which provides a novel insight that the SMI-to-BMI ratio may be superior to BMI or SMI as an indicator of postsurgical bleeding.

From another point of view regarding the association between SMI and BMI, sarcopenic obesity has gained significant attention in the field of cancer treatment [17–20]. Since Prado et al. had first profiled sarcopenic obesity in relation to the mortality risk in solid malignancies [24], numerous reports have demonstrated that sarcopenic obesity has a negative effect on the outcomes of patients with cancer [17–20]. Moreover, currently, obese patients with reduced skeletal muscle mass are at a special risk for adverse outcomes [17]. In line with this, the present study showed that patients with low SMI and high BMI had the highest risk of postsurgical bleeding. These findings support the notion that a combination of SMI and BMI can provide a more accurate marker for predicting the risk of postsurgical bleeding than either SMI or BMI alone.

Univariate analysis revealed that the axillary procedure was associated with the risk of postsurgical bleeding (Table 3). In general, the dissected area is larger in mastectomy plus Ax than in mastectomy plus SLNB, suggesting a higher risk of postsurgical bleeding in the former than in the latter. Nonetheless, this study showed that mastectomy plus Ax was associated with a lower risk of postsurgical bleeding. This paradoxical result suggests that surgeons tend to confirm hemostasis more thoroughly with mastectomy plus Ax than with mastectomy plus SLNB. Another possible explanation is that the bleeding point after mastectomy is more likely to be on the surface of the pectoralis major muscle, rather than in the axillary area. Recently, pectoralis major muscle area (PMA) has been utilized to characterize sarcopenia, as well as SMA, in patients with breast cancer [25, 26]. Hence, patients with sarcopenia may have an atrophic pectoralis major muscle, which can be related to the increased vulnerability of the blood vessels in the pectoralis major muscle and an increased risk of bleeding. Further studies exploring the association between SMA and PMA and the correlation between PMA and the risk of postsurgical bleeding are warranted.

This study has some limitations. First, this was a retrospective analysis with a relatively small patient cohort from a single institution in an Asian country. Second, the cutoff values of BMI, SMI, and SMI-to-BMI ratio were determined using data from the patient cohort in this study, in which all patients were Japanese. Although our results indicated the utility of the SMI-to-BMI ratio as an indicator of postsurgical bleeding after mastectomy, we could not conclude that the effect of the SMI-to-BMI ratio was equally applicable to other races with different body compositions. Furthermore, although we previously demonstrated that NAC could induce a decrease in SMI [27], none of the patients receiving NAC experienced postsurgical bleeding in this study. Although this is at least partly due to the fact that 91.9% of patients who were treated with NAC (125 out of 136 patients) underwent mastectomy plus Ax, which is associated with a low risk of postsurgical bleeding, the association between NAC and the risk of postsurgical bleeding should be further explored. Large-scale studies with different patient cohorts are warranted to overcome these limitations and validate our results.

The findings of this study indicate that SMI-to-BMI ratio is a superior predictor of postsurgical bleeding to either BMI or SMI alone. Our results underscore the importance of skeletal muscle mass for body weight as a marker of outcomes in patients with cancer.

Acknowledgement: We would like to thank Editage (www.editage.com) for English language editing.

Conflict of interest: The authors declare that they have no competing interests.

Ethics approval and consent to participate: This study was approved by the Medical Ethics Committee on Clinical Investigation of Shinshu University (no. 5037). Patients were provided the opportunity to opt out of participation in this study via notifications displayed in the outpatient ward and the institution’s website. Unless patients reject the enrollment in this study, the requirement for written informed consent was waived by the Medical Ethics Committee on Clinical Investigation of Shinshu University. This study was conducted in accordance with the principles laid down in the Declaration of Helsinki.

Availability of data and material: The data supporting the findings of this work are available from the authors upon reasonable request.

Funding: This work was not funded by any grant.

Authors’ contributions: Hiroki Morikawa and Takaaki Oba designed the study. Nami Kiyosawa, Ryoko Iji, Masatsugu Amitani, Tatsunori Chino, Tadafumi Sshimizu, Mayu Ono, Tokiko Ito, Toshiharu Kanai, Kazuma Maeno collected the clinical data. Hiroki Morikawa and Takaaki Oba performed the statistical analysis. The draft manuscript was prepared by Hiroki Morikawa, Takaaki Oba and Ken-ichi Ito. All authors read and approved the final manuscript.

Miller KD, Ortiz AP, Pinheiro PS, Bandi P, Minihan A, Fuchs HE, et al. Cancer statistics for the US Hispanic/Latino population, 2021. CA Cancer J Clin 2021.doi: 10.3322/caac.21695.
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227–32.doi: 10.1056/NEJMoa020989.
Habermann EB, Abbott A, Parsons HM, Virnig BA, Al-Refaie WB, Tuttle TM. Are mastectomy rates really increasing in the United States? J Clin Oncol 2010;28:3437–41.doi: 10.1200/jco.2009.27.6774.
Pagliara D, Schiavone L, Garganese G, Bove S, Montella RA, Costantini M, et al. Predicting Mastectomy Skin Flap Necrosis: A Systematic Review of Preoperative and Intraoperative Assessment Techniques. Clin Breast Cancer 2023.doi: 10.1016/j.clbc.2022.12.021.
Olsen MA, Lefta M, Dietz JR, Brandt KE, Aft R, Matthews R, et al. Risk factors for surgical site infection after major breast operation. J Am Coll Surg 2008;207:326 – 35.doi: 10.1016/j.jamcollsurg.2008.04.021.
El-Tamer MB, Ward BM, Schifftner T, Neumayer L, Khuri S, Henderson W. Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg 2007;245:665–71.doi: 10.1097/01.sla.0000245833.48399.9a.
de Blacam C, Ogunleye AA, Momoh AO, Colakoglu S, Tobias AM, Sharma R, et al. High body mass index and smoking predict morbidity in breast cancer surgery: a multivariate analysis of 26,988 patients from the national surgical quality improvement program database. Ann Surg 2012;255:551–5.doi: 10.1097/SLA.0b013e318246c294.
Garland M, Hsu FC, Clark C, Chiba A, Howard-McNatt M. The impact of obesity on outcomes for patients undergoing mastectomy using the ACS-NSQIP data set. Breast Cancer Res Treat 2018;168:723 – 26.doi: 10.1007/s10549-017-4651-4.
Pastoriza J, McNelis J, Parsikia A, Lewis E, Ward M, Marini CP, et al. Predictive Factors for Surgical Site Infections in Patients Undergoing Surgery for Breast Carcinoma. Am Surg 2021;87:68–76.doi: 10.1177/0003134820949996.
Wang M, Huang J, Chagpar AB. Do Obese Breast Cancer Patients Have More Complications and a Longer Length of Stay After Mastectomy Than Nonobese Patients? Am Surg 2021;87:1099–106.doi: 10.1177/0003134820973352.
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16–31.doi: 10.1093/ageing/afy169.
Madariaga MLL, Troschel FM, Best TD, Knoll SJ, Gaissert HA, Fintelmann FJ. Low Thoracic Skeletal Muscle Area Predicts Morbidity After Pneumonectomy for Lung Cancer. Ann Thorac Surg 2020;109:907 – 13.doi: 10.1016/j.athoracsur.2019.10.041.
Uehara H, Yamazaki T, Iwaya A, Kameyama H, Utsumi S, Harada R, et al. Is radiological psoas muscle area measurement a predictor of postoperative complications after rectal resection for rectal cancer? A retrospective study. Surg Today 2021.doi: 10.1007/s00595-021-02346-x.
Lodewick TM, Roeth AA, Olde Damink SW, Alizai PH, van Dam RM, Gassler N, et al. Sarcopenia, obesity and sarcopenic obesity: effects on liver function and volume in patients scheduled for major liver resection. J Cachexia Sarcopenia Muscle 2015;6:155 – 63.doi: 10.1002/jcsm.12018.
Nishimura JM, Ansari AZ, D'Souza DM, Moffatt-Bruce SD, Merritt RE, Kneuertz PJ. Computed Tomography-Assessed Skeletal Muscle Mass as a Predictor of Outcomes in Lung Cancer Surgery. Ann Thorac Surg 2019;108:1555-64.doi: 10.1016/j.athoracsur.2019.04.090.
Kamarajah SK, Bundred J, Tan BHL. Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2019;22:10–22.doi: 10.1007/s10120-018-0882-2.
Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol 2018;29:ii1-ii9.doi: 10.1093/annonc/mdx810.
Kobayashi A, Kaido T, Hamaguchi Y, Okumura S, Shirai H, Yao S, et al. Impact of Sarcopenic Obesity on Outcomes in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Ann Surg 2019;269:924–31.doi: 10.1097/sla.0000000000002555.
Mizuno S, Seishima R, Okabayashi K, Shigeta K, Matsui S, Kitagawa Y. Sarcopenic obesity is a postoperative prognostic factor for stage II and III colorectal cancer. J Gastrointest Surg 2021;25:2951–53.doi: 10.1007/s11605-021-04965-8.
Stangl-Kremser J, Mari A, Lai LY, Lee CT, Vince R, Zaslavsky A, et al. Sarcopenic Obesity and Its Prognostic Impact on Urologic Cancers: A Systematic Review. J Urol 2021:101097ju0000000000001873.doi: 10.1097/ju.0000000000001873.
Winther Lietzen L, Cronin-Fenton D, Garne JP, Kroman N, Silliman R, Lash TL. Predictors of re-operation due to post-surgical bleeding in breast cancer patients: a Danish population-based cohort study. Eur J Surg Oncol 2012;38:407 – 12.doi: 10.1016/j.ejso.2012.02.184.
Jochum SB, Kistner M, Wood EH, Hoscheit M, Nowak L, Poirier J, et al. Is sarcopenia a better predictor of complications than body mass index? Sarcopenia and surgical outcomes in patients with rectal cancer. Colorectal Dis 2019;21:1372–78.doi: 10.1111/codi.14751.
Matsui R, Inaki N, Tsuji T. Impact of preoperative muscle quality on postoperative severe complications after radical gastrectomy for gastric cancer patients. Ann Gastroenterol Surg 2021;5:510 – 18.doi: 10.1002/ags3.12452.
Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:629 – 35.doi: 10.1016/s1470-2045(08)70153-0.
Rossi F, Lambertini M, Brunetti N, De Giorgis S, Razeti MG, Calabrese M, et al. Muscle mass loss in breast cancer patients of reproductive age (≤ 45 years) undergoing neoadjuvant chemotherapy. Radiol Med 2023;128:49–57.doi: 10.1007/s11547-022-01574-6.
Song HN, Kim JY, Kim JM, Kang KM, Choi HS, Jeong JH, et al. Sarcopenia using pectoralis muscle area and lymphocyte-to-monocyte ratio (LMR) are independent prognostic factors in patients for nonmetastatic breast cancer. Medicine (Baltimore) 2022;101:e32229.doi: 10.1097/md.0000000000032229.
Amitani M, Oba T, Kiyosawa N, Morikawa H, Chino T, Soma A, et al. Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer. BMC Cancer 2022;22:327.doi: 10.1186/s12885-022-09443-1.

Table 4 is not available with this version

SupplementaryTable1.docx

Download PDF

Journal Publication

published 12 Jul, 2023

Read the published version in Breast Cancer →

Reviewers agreed at journal
01 May, 2023
Reviewers invited by journal
01 May, 2023
Editor assigned by journal
26 Apr, 2023
First submitted to journal
25 Apr, 2023

You are reading this latest preprint version

Skeletal muscle index-to-body mass index ratio as a predictor of postsurgical bleeding after mastectomy in patients with breast cancer

Status:

Journal Publication

Version 1

Abstract

Figures

Background

Methods

Patients and study design

Data collection

Definition of postsurgical bleeding

Measurement of skeletal muscle index (SMI)-to-body mass index (BMI) ratio

Statistical analyses

Results

Patient characteristics

Comparison of clinicopathological characteristics according to the presence of postsurgical bleeding

Comparison of postoperative course according to the presence of postsurgical bleeding

Correlation between preoperative SMI and BMI

Impact of SMI-to-BMI ratio as a risk factor for postsurgical bleeding

Impact of sarcopenic obesity as a risk factor for postsurgical bleeding

Discussion

Conclusions

Declarations

References

Tables

Supplementary Files

Status:

Journal Publication

Version 1